Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network

xlomafota13 shared this article with you from Inoreader Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network Via Association française pour l'étude du cancer Bull Cancer. 2021 Sep 27:S0007-4551(21)00303-9. doi: 10.1016/j.bulcan.2021.06.009. Online ahead of print. ABSTRACT Refractory thyroid cancers include radio-iodine-refractory cancers, metastatic or locally advanced unresectable medullary and anaplastic thyroid cancers. Their management has been based for several years on the use of multi-target kinase inhibitors, with anti-angiogenic action, with the exception of anaplastic cancers usually treated with chemo- and radiotherapy. The situation has recently evolved due to the availability of molecular genotyping techniques allowing the discovery of rare but targetable molecular abnormalities. New treatment options have become available, more effective and less toxic than the previously available multi-target kinase inhibitors. The management of refractory thyroid cancers is therefore becoming more complex both at a diagnosis level with the need to know when, how and why to look for these mo lecular abnormalities but also at a therapeutic level, innovative treatments being hardly accessible. The cost of molecular analyzes and the access to treatments need also to be homogenized because disparities could lead to inequality of care at a national or international level. Finally, the strategy of identifying molecular alterations and treating these rare tumors reinforces the importance of a discussion in a multidisciplinary consultation meeting. PMID:34593218 | DOI:10.1016/j.bulcan.2021.06.009 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.